Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63709178 in Relapsed or Refractory AML
NCT02715011Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Mar 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of JNJ-63709178 in acute myeloid leukemia (AML) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 1.5 years. Started Jun 2016; status: completed.
02
Drugs
JNJ-63709178
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02715011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715011.